AR040779A1 - Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion - Google Patents

Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion

Info

Publication number
AR040779A1
AR040779A1 AR20030102791A ARP030102791A AR040779A1 AR 040779 A1 AR040779 A1 AR 040779A1 AR 20030102791 A AR20030102791 A AR 20030102791A AR P030102791 A ARP030102791 A AR P030102791A AR 040779 A1 AR040779 A1 AR 040779A1
Authority
AR
Argentina
Prior art keywords
alkyl
formulation
group
compound
prepare
Prior art date
Application number
AR20030102791A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040779A1 publication Critical patent/AR040779A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de tiazol anilina de la fórmula (1) en la que: el tiazol está en orto con respecto al N; R1 se selecciona del grupo constituido por halógeno, alquilo C1-5, CH2F, CHF2; R2 se selecciona del grupo constituido por H, alquilo C1-5, arilo, halógeno, hidroxi y alcoxi; R3 se selecciona del grupo constituido por H, alquilo C1-5, cicloalquilo, cicloalquil-alquilo C1-5, alquenilo C2-4,alquenil C2-4-arilo; cicloalquil alquilo C1-5 y alquil C1-4-arilo, que pueden estar opcionalmente sustituidos independientemente con un sustituyente seleccionado del grupo constituido por halógeno, nitro, alquilo C1-4 halosustituido, alquilo C1-4, amino, amino mono- o di-sustituido con alquilo C1-4, ORa, -C(O)Ra, NRaC(O)ORa, OC(O)NR6R7, hidroxi, NR9C(O)Ra, S(O)mRa, C(O)NR6R7, C(O)OH, C(O)ORa, S(O)2NR6R7 y NHS(O)2Ra; R6 y R7 se seleccionan del grupo constituido por H y alquilo C1-4 o R6 y R7 juntos forman un anillo de 5 a 7 elementos, anillo que puede contener opcionalmente un heteroátomo adicional seleccionado de O, N o S y cuyo anillo puede estar opcionalmente sustituido; n es 1 o 2; e independientemente m es 1 o 2. Uso de un compuesto de fórmula (1) para preparar una formulación farmacéutica de utilidad en un procedimiento de antagonización del receptor muscarínico M3 de acetilcolina y dicha formulación. Recipiente provisto de una válvula dosificadora que contiene la formulación farmacéutica y dispositivo adaptado para la administración intranasal de dicha formulación que comprende dicho recipiente.
AR20030102791A 2002-08-06 2003-08-04 Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion AR040779A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40175602P 2002-08-06 2002-08-06

Publications (1)

Publication Number Publication Date
AR040779A1 true AR040779A1 (es) 2005-04-20

Family

ID=31495981

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102791A AR040779A1 (es) 2002-08-06 2003-08-04 Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion

Country Status (9)

Country Link
US (1) US20050277676A1 (es)
EP (1) EP1549278A4 (es)
JP (1) JP2006505517A (es)
AR (1) AR040779A1 (es)
AU (1) AU2003261392A1 (es)
PE (1) PE20040892A1 (es)
TW (1) TW200410951A (es)
UY (1) UY27927A1 (es)
WO (1) WO2004012684A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
PE20050250A1 (es) 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
DE602004030930D1 (de) 2003-10-14 2011-02-17 Glaxo Group Ltd Muscarinische acetylcholin-rezeptor-antagonisten
OA13270A (en) * 2003-10-17 2007-01-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
US7265133B2 (en) 2004-03-11 2007-09-04 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087736A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7560469B2 (en) 2004-03-11 2009-07-14 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087739A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087734A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
US7456199B2 (en) 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2007529511A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
US7598267B2 (en) * 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US20080287487A1 (en) * 2004-06-30 2008-11-20 Anthony William James Cooper Muscarinic Acetylcholine Receptor Antagonists
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006024483A1 (en) * 2004-09-01 2006-03-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with muscarinic acetylcholine receptor 3 (acm3)
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7642355B2 (en) 2005-03-10 2010-01-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008537931A (ja) 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1856112A1 (en) 2005-03-10 2007-11-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006138218A1 (en) 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2009503099A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2007280195A (ja) * 2006-04-10 2007-10-25 Pfu Ltd 内部統制システム
WO2008041184A2 (en) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8367696B2 (en) 2007-02-09 2013-02-05 Astellas Pharma Inc. Aza-bridged-ring compound
AR070562A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091553A1 (es) 2008-02-06 2009-10-30 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2732066T3 (es) * 2014-06-06 2019-11-20 Astellas Pharma Inc Derivado de 2-acilaminotiazol para su uso en la prevención o el tratamiento de enfermedades de la vejiga/vías urinarias

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2542822B1 (fr) * 1983-03-15 1985-07-12 Procedes Tech Const Dispositif de regulation d'une eolienne comportant un panneau de commande d'effacement basculant sous la commande d'un panneau auxiliaire
US20020052007A1 (en) * 1992-02-03 2002-05-02 Chang Kwen Jen Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives
GB9909612D0 (en) * 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU2002357312A1 (en) * 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases

Also Published As

Publication number Publication date
US20050277676A1 (en) 2005-12-15
TW200410951A (en) 2004-07-01
UY27927A1 (es) 2003-12-31
WO2004012684A3 (en) 2004-06-24
AU2003261392A1 (en) 2004-02-23
EP1549278A4 (en) 2005-12-14
PE20040892A1 (es) 2004-11-19
WO2004012684A2 (en) 2004-02-12
EP1549278A2 (en) 2005-07-06
JP2006505517A (ja) 2006-02-16
AU2003261392A8 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
AR040779A1 (es) Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
ECSP12011867A (es) Derivados bencimidazol-imidazol
AR106013A1 (es) Conjugados de anticuerpos modificados con cisteína
AR109033A2 (es) Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso
AR061134A1 (es) Derivados de tioxantina
PE20040479A1 (es) Inhibidores de proteasa del vih y composiciones que los contienen
CU23288B7 (es) DERIVADOS DE TROPANO ÃsTILES EN TERAPIA
ES2182535T3 (es) Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
AR075892A1 (es) Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
AR053994A1 (es) Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos
ES2186251T3 (es) Nuevos derivados de acilguanidina como inhibidores de la resorcion de los huesos y como antagonistas de receptores de vitronectina.
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
AR078786A1 (es) Derivados de la cromenona
CO5450245A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
BR112016014595A8 (pt) material à base de sólido para uso tópico sobre a pele,composição aquosa e método de produção do mesmo.
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
BR112012033465A2 (pt) método para preparar um composto
MX2022002339A (es) Derivados de alfa-d-galactopiranosido.
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR058077A1 (es) Derivados de acidos fenoxiaceticos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal